November 6, 2023
A team of researchers have identified epigenomic drivers associated with cancer development and progression, constructing a pan-cancer epigenetic and transcriptomic atlas from the data. This atlas […]
April 18, 2023
ROCKVILLE, Md., April 18, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help […]
April 3, 2023
https://nationalcancerplan.cancer.gov/ We know that our continued progress against cancer is the direct result of advances made possible by investment from federal, state, and local governments, along […]
March 14, 2023
On March 7, 2023, Robert Snyder, PhD, Associate Director of Genomics at Precision for Medicine, delivered a presentation entitled, Biobank Partnering for Clinical Trial Assay / CDx […]
February 15, 2023
SAN FRANCISCO, Feb. 2, 2023 /PRNewswire/ — Qvin™, the biotechnology company that developed the first and only healthcare service that scientifically collects menstrual blood to test for HR-HPV and […]
December 13, 2022
ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help […]
November 15, 2022
InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker […]
October 25, 2022
ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to […]
October 12, 2022
Cologne/Berlin, Germany, and Boston, MA, USA, October 12, 2022 – InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for […]
